Long-term interferon therapy after radiofrequency ablation is effective in treating patients with HCV-associated hepatocellular carcinoma

Hepatology International

Volumn 5, Issue 1, 2011, Pages 559-566

  Shimomura, Soji ^a   Ikeda, Naoto ^a   Saito, Masaki ^a   Ishii, Akio ^a   Takashima, Tomoyuki ^a   Sakai, Yoshiyuki ^a   Yoshikawa, Shohei ^a   Aizawa, Nobuhiro ^a   Tanaka, Hironori ^a   Iwata, Yoshinori ^a   Enomoto, Hirayuki ^a   Imanishi, Hiroyasu ^a   Yamamoto, Teruhisa ^b   Jomura, Hisato ^c   Nakamura, Hideji ^a   Iijima, Hiroko ^a   Nishiguchi, Shuhei ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

^b Wakakusa Daiichi Hospital   (Japan)

^c Wakakoukai Hospital   (Japan)

Author keywords

Hepatitis C virus; Hepatocellular carcinoma; Interferon; Prevention; Radiofrequency ablation

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALPHA INTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CHRONIC DRUG ADMINISTRATION; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; FEMALE; HEPATITIS C VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER FUNCTION TEST; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; RETROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VIRUS CARCINOGENESIS;

EID: 79952624302     PISSN: 19360533     EISSN: 19360541     Source Type: Journal    
DOI: 10.1007/s12072-010-9214-2     Document Type: Article

References (33)

1. B Hashem R Lenhard 2007 Hepatocellular carcinoma: epidemiology and molecular carcinogenesis Gastroenterology 132 2557 2576 10.1053/j.gastro.2007. 04.061 (Pubitemid 46890874)
2. K Koike T Tsutsumi H Fujie Y Shintani K Moriya 2002 Molecular mechanism of viral hepatocarcinogenesis Oncology 62 Suppl 19 29 37 10.1159/000048273 11868782 (Pubitemid 34702017)
3. H Imamura Y Matsuyama E Tanaka T Ohkubo K Hasegawa S Miyagawa Y Sugawara M Minagawa T Takayama S Kawasaki M Makuuchi 2003 Risk factor contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy J Hepatol 38 200 203 10.1016/S0168-8278(02)00360-4 12547409 (Pubitemid 36169630)
4. K Ikeda Y Arase M Kobayashi S Saitoh T Someya T Hosaka Y Suzuki F Suzuki A Tsubota N Akuta H Kumada 2003 Significance of multicentric cancer recurrence after potentially curative ablation of hepatocellular carcinoma: a longterm cohort study of 892 patients with viral cirrhosis J Gastroenterol 38 865 876 10.1007/s00535-003-1163-2 14569444 (Pubitemid 37322034)
5. S Nishiguchi T Kuroki S Nakatani H Morimoto T Takeda S Nakajima S Shiomi S Seki K Kobayashi S Otani 1995 Randomised trial of effects of Interferon-α on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis Lancet 346 1051 1055 1:CAS:528:DyaK2MXpsl2lurY%3D 10.1016/S0140-6736(95)91739-X 7564784
6. S Nishiguchi S Shiomi S Nakatani T Takeda K Fukuda A Tamori D Habu T Tanaka 2001 Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis Lancet 357 196 197 1:STN:280: DC%2BD3M7kvFCitQ%3D%3D 10.1016/S0140-6736(00)03595-9 11213099 (Pubitemid 32108094)
7. H Yoshida Y Arakawa M Sata S Nishiguchi M Yano S Fujiyama G Yamada O Yokosuka Y Shiratori M Omata 2002 Interferon therapy prolonged life expectancy among chronic hepatitis C patients Gastroenterology 123 483 491 1:CAS:528:DC%2BD38XmsFahtL8%3D 10.1053/gast.2002.34785 12145802 (Pubitemid 34827193)
8. Y Shiratori Y Ito O Yokosuka F Imazeki R Nakata N Tanaka Y Arakawa E Hashimoto K Hirata H Yoshida Y Ohashi M Omata 2005 Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival Ann Intern Med 142 105 114 1:CAS:528:DC%2BD2MXktVequ74%3D 15657158
9. M Kurokawa N Hiramatsu T Oze K Mochizuki T Yakushijin N Kurashige Y Inoue T Igura K Imanaka A Yamada M Oshita H Hagiwara T Ito Y Inui T Hijioka H Yoshihara A Inoue Y Imai M Kato S Kiso T Kanto T Takehara A Kasahara N Hayashi 2009 Effect of interferon α-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with chronic hepatitis Hepatol Res 39 432 438 1:CAS:528:DC%2BD1MXhsFemsbnM 10.1111/j.1872-034X.2008.00477.x 19207583
10. K Ikeda Y Arase S Saitoh M Kobayashi Y Suzuki F Suzuki A Tsubota K Chayama N Murashima H Kumada 2000 Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor - a prospective randomized study of hepatitis C virus-related liver cancer Hepatology 32 228 232 1:CAS:528:DC%2BD3cXlvVyjtrk%3D 10.1053/jhep.2000.9409 10915728 (Pubitemid 30614654)
11. S Kubo S Nishiguchi K Hirohashi H Tanaka T Shuto H Kinoshita 2002 Randomized clinical trial of long-term outcome after resection of hepatitis C virus-related hapatocellular carcinoma by postoperative interferon therapy Br J Surg 89 418 422 1:STN:280:DC%2BD383hs1KrtQ%3D%3D 10.1046/j.0007-1323.2001.02054. x 11952580 (Pubitemid 34595504)
12. Y Shiratori S Shiina T Teratani M Imamura S Obi S Sato Y Koike H Yoshida M Omata 2003 Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus Ann Intern Med 138 299 306 12585827 (Pubitemid 36205926)
13. S Nishiguchi A Tamori S Kubo 2005 Effect of long-term postoperative interferon therapy on intrahepatic recurrence and survival rate after resection of hepatitis C virus-related hepatocellular carcinoma Intervirology 48 71 75 1:CAS:528:DC%2BD2MXisFyhtLw%3D 10.1159/000082098 15785093 (Pubitemid 40529214)
14. SC Jeong H Aikata Y Katamura T Azakami T Kuwaoka H Saneto K Uka N Mori S Takaki H Kodama K Waki M Imamura H Shirakawa Y Kawakami S Takahashi K Chayama 2007 Effects of a 24-week course of interferon-α therapy after curative treatment of hepatitis C virus- associated hepatocellular carcinoma World J Gastroenterol 13 5343 5350 17879404 (Pubitemid 47559465)
15. M Kudo Y Sakaguchi H Chung K Hatanaka S Hagiwara E Ishikawa S Takahashi S Kitai T Inoue Y Minami K Ueshima 2007 Long-term interferon maintenance therapy improves survival in patients with hepatitis C virus-related hepatocellular carcinoma after curative radiofrequency ablation Oncology 72 Suppl 1 132 138 1:CAS:528:DC%2BD2sXhsVels7fM 10.1159/000111719 18087194 (Pubitemid 350256677)
16. V Mazzaferro R Romito M Schiavo L Mariani T Camerini S Bhoori L Capussotti F Calise R Pellicci G Belli A Tagger M Colombo F Bonino P Majno JM Liovet 2006 Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in hepatitis C virus cirrhosis Hepatology 44 1543 1554 1:CAS:528:DC%2BD2sXislKktQ%3D%3D 10.1002/hep.21415 17133492 (Pubitemid 44970357)
17. PR Rosenbaum DB Rubin 1983 The central role of the propensity score in observational studies for causal effects Biometrika 70 41 55 10.1093/biomet/70.1.41
18. RB D'Agostino Jr 1998 Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group Stat Med 17 2265 2281 10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B 9802183 (Pubitemid 28466823)
19. M Minagawa I Ikai Y Matsuyama Y Yamaoka M Makuuchi 2007 Staging of hepatocellular carcinoma: assessment of the Japanese Tumor-Node-Metastasis and American Joint Committee on Cancer/International Union Against Cancer Tumor-Node-Metastasis systems in a cohort of 13,772 patients in Japan Ann Surg 245 909 922 10.1097/01.sla.0000254368.65878.da 17522517 (Pubitemid 46809293)
20. S Weitzen KL Lapane AY Toledano AL Hume V Mor 2005 Weaknesses of goodness-of-fit tests for evaluating propensity score models Pharmacoepidemiol Drug Saf 14 227 238 10.1002/pds.986 15386700 (Pubitemid 40528852)
21. K Koike 2007 Pathogenesis of hepatitis C virus-associated hepatocellular carcinoma: dual-pass carcinogenesis through activation of oxidative stress and intracellular signaling Hepatol Res 37 115 120 10.1111/j.1872-034X.2007.00173.x
22. T Kumada S Nakano I Takeda K Sugiyama T Osada S Kiriyama Y Sone H Toyoda S Shimada M Takahashi T Sassa 1997 Pattern of recurrence after initial treatment in patients with small hepatocellular carcinoma Hepatology 25 87 92 1:STN:280:DyaK2s7jvVantg%3D%3D 10.1002/hep.510250116 8985270 (Pubitemid 27014990)
23. H Tsukuma T Hiyama S Tanaka M Nakao T Yabuubhi T Kitamura K Nakanishi I Fujimoto A Inoue H Yamazaki T Kawashima 1993 Risk factors for hepatocellular carcinoma among patients with chronic liver disease N Engl J Med 328 1797 1801 1:STN:280:DyaK3s3nsFektg%3D%3D 10.1056/NEJM199306243282501 7684822 (Pubitemid 23174709)
24. TJ Iwashyna EB Lamont 2002 Effectiveness of adjuvant fluorouracil in clinical practice: a population-based cohort study of elderly patients with stage III colon cancer J Clin Oncol 20 3992 3998 1:CAS:528:DC%2BD38XntF2jsLk%3D 10.1200/JCO.2002.03.083 12351596
25. PS Wang S Schneeweiss J Avorn MA Fischer H Mogun DH Solomon MA Brookhart 2005 Risk of death in elderly users of conventional versus atypical antipsychotic medications N Engl J Med 353 2335 2341 1:CAS:528: DC%2BD2MXht1OmsbrI 10.1056/NEJMoa052827 16319382 (Pubitemid 41713745)
26. H Yano A Iemura M Haramaki S Ogasawara A Takayama J Akiba M Kojiro 1999 Interferon alfa receptor expression and growth inhibition by interferon alfa in human liver cancer cell lines Hepatology 29 1708 1717 1:CAS:528: DyaK1MXjvFOmsL8%3D 10.1002/hep.510290624 10347112 (Pubitemid 29247043)
27. CL Lai JY Lau PC Wu H Ngan HT Chung S Mitchell TJ Corbett AW Chow HJ Lin 1993 Recombinant interferon-alpha in inoperable hepatocellular carcinoma: a randomized controlled trial Hepatology 17 389 394 1:STN:280:DyaK3s7os1Sluw%3D%3D 10.1002/hep.1840170307 8383088 (Pubitemid 23072812)
28. H Ota H Nagano M Sakon H Eguchi M Kondo T Yamamoto M Nakamura B Damdinsuren H Wada S Marubashi A Miyamoto K Done K Umeshita S Nakamori K Wakasa M Monden 2005 Treatment of hepatocellular carcinoma with major portal vein thrombosis by combination of subcutaneous interferon-α and intraarterial 5-fluorouracil: role of expression of type 1 interferon receptor Br J Cancer 93 557 564 1:CAS:528:DC%2BD2MXpsFalurg%3D 10.1038/sj.bjc.6602742 16106266 (Pubitemid 43079999)
29. H Yano S Ogasawara S Momosaki J Akiba S Kojiro S Fukahori H Ishizaki K Kuratomi Y Basaki S Oie M Kuwano M Kojiro 2006 Growth inhibitory effects of pegylated interferon alpha-2b on human liver cancer cells in vitro and in vivo Liver Int 26 964 975 1:CAS:528:DC%2BD28XhtF2qsbzE 10.1111/j.1478-3231.2006. 01321.x 16953837 (Pubitemid 44323415)
30. L Wang ZY Tang LX Qin XF Wu HC Sun Q Xue SL Ye 2000 High-dose and long-term therapy with interferon-alfa inhibits tumor growth and recurrence in nude mice bearing human hepatocellular carcinoma xenografts with high metastatic potential Hepatology 32 43 48 1:CAS:528:DC%2BD3cXltFWgs74%3D 10.1053/jhep.2000.8525 10869287 (Pubitemid 30432364)
31. T Uenishi S Nishiguchi A Tamori T Yamamoto T Shuto K Hirohashi S Takemura H Tanaka S Kubo 2006 Influence of interferon therapy on outcome after surgery for hepatitis C virus-related hepatocellular carcinoma Hepatol Res 36 195 200 1:CAS:528:DC%2BD28XhtFSktbvE 10.1016/j.hepres.2006.07.011 16934521 (Pubitemid 44575933)
32. CH Zhang GL Xu WD Jia YS Ge 2009 Effects of interferon alpha treatment on recurrence and survival after complete resection or ablation of hepatocellular carcinoma: a meta-analysis of randomized controlled trials Int J Cancer 124 2982 2988 1:CAS:528:DC%2BD1MXltlCguro%3D 10.1002/ijc.24311 19296539
33. YC Shen C Hsu LT Chen CC Cheng FC Hu AL Cheng 2010 Adjuvant interferon therapy after curative therapy for hepatocellular carcinoma (HCC): a meta-regression approach J Hepatol 52 889 894 1:CAS:528:DC%2BC3cXmsVeju74%3D 10.1016/j.jhep.2009.12.041 20395009